Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Agios Pharmaceuticals
company
About
Agios Pharmaceuticals is a biopharmaceutical company discovers and develops therapeutics in the field of cancer metabolism.
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $78M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2008
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$111M
Agios Pharmaceuticals has raised a total of
$111M
in funding over 2 rounds. Their latest funding was raised on
Nov 17, 2011 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 17, 2011 | Series C | $78M | 1 | — | — | Detail |
| Jul 7, 2008 | Series A | $33M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Agios Pharmaceuticals is funded by 1 investors.
ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
